CL2022002642A1 - Medicamentos para fibrosis pulmonar que contienen derivado de pirazol - Google Patents
Medicamentos para fibrosis pulmonar que contienen derivado de pirazolInfo
- Publication number
- CL2022002642A1 CL2022002642A1 CL2022002642A CL2022002642A CL2022002642A1 CL 2022002642 A1 CL2022002642 A1 CL 2022002642A1 CL 2022002642 A CL2022002642 A CL 2022002642A CL 2022002642 A CL2022002642 A CL 2022002642A CL 2022002642 A1 CL2022002642 A1 CL 2022002642A1
- Authority
- CL
- Chile
- Prior art keywords
- pulmonary fibrosis
- drugs
- pyrazole derivative
- containing pyrazole
- fibrosis containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención provee una composición farmacéutica o un agente antiviral para el tratamiento de fibrosis pulmonar, que comprende un compuesto de la Fórmula 1, que es un derivado de pirazol, o una sal farmacéuticamente aceptable del mismo.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200044598 | 2020-04-13 | ||
| KR1020210036863A KR102386097B1 (ko) | 2020-04-13 | 2021-03-22 | 피라졸 유도체의 폐섬유증 치료제 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2022002642A1 true CL2022002642A1 (es) | 2023-06-16 |
Family
ID=78083982
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2022002642A CL2022002642A1 (es) | 2020-04-13 | 2022-09-27 | Medicamentos para fibrosis pulmonar que contienen derivado de pirazol |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230148365A1 (es) |
| EP (1) | EP4137134A1 (es) |
| JP (1) | JP2023522628A (es) |
| KR (2) | KR102567012B1 (es) |
| CN (1) | CN115427039A (es) |
| AU (1) | AU2021255160B2 (es) |
| BR (1) | BR112022020649A2 (es) |
| CA (1) | CA3172596A1 (es) |
| CL (1) | CL2022002642A1 (es) |
| CO (1) | CO2022014273A2 (es) |
| MX (1) | MX2022012726A (es) |
| WO (1) | WO2021210799A1 (es) |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20040094464A (ko) * | 2003-05-02 | 2004-11-10 | 학교법인 이화학당 | 피리디닐 피라졸 유도체 |
| WO2011028043A2 (ko) | 2009-09-02 | 2011-03-10 | 이화여자대학교 산학협력단 | 피라졸 유도체, 이의 제조방법 및 이를 포함하는 골다공증 예방 및 치료용 조성물 |
| KR101302315B1 (ko) * | 2011-07-19 | 2013-08-30 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 호흡기 질환 예방 및 치료용 조성물 |
| KR101633957B1 (ko) * | 2012-08-27 | 2016-06-27 | 이화여자대학교 산학협력단 | 피라졸 유도체를 포함하는 신장질환 예방 또는 치료용 조성물 |
| CA2952069C (en) * | 2014-06-16 | 2022-06-14 | University Of Rochester | Small molecule anti-scarring agents |
| US11096952B2 (en) * | 2016-02-02 | 2021-08-24 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Chemicals and methods to prevent and treat TGF-beta mediated activation of fibroblasts to reduce and treat cancer and fibrosis |
| KR101821593B1 (ko) * | 2017-02-23 | 2018-01-25 | 압타바이오 주식회사 | 안질환 치료제 |
| US11191749B2 (en) | 2017-03-13 | 2021-12-07 | Genfit | Pharmaceutical compositions for combination therapy |
| EP3612175A1 (en) | 2017-04-18 | 2020-02-26 | Genfit | Combination of elafibranor or derivatives thereof with an anti-nash, anti-fibrotic or anti-cholestatic agent |
| KR101856444B1 (ko) * | 2017-04-20 | 2018-05-10 | 압타바이오 주식회사 | 3-페닐-4-프로필-1-(피리딘-2-일)-1ｈ-피라졸-5-올 염산염의 신규 결정형 고체 화합물 |
| KR101840702B1 (ko) * | 2017-11-01 | 2018-03-22 | 압타바이오 주식회사 | 간질환 치료제 |
| TWI815938B (zh) | 2018-08-01 | 2023-09-21 | 日商日本化藥股份有限公司 | 具有n-烷基的芳香族胺樹脂、硬化性樹脂組成物及其硬化物 |
| EP3628669A1 (en) * | 2018-09-28 | 2020-04-01 | GenKyoTex Suisse SA | Novel compounds as nadph oxidase inhibitors |
| KR102207340B1 (ko) | 2018-10-19 | 2021-01-22 | 한남대학교 산학협력단 | 표면 개질된 다공성 탄소복합소재 및 그 제조방법 |
-
2021
- 2021-03-23 EP EP21787824.8A patent/EP4137134A1/en active Pending
- 2021-03-23 WO PCT/KR2021/003537 patent/WO2021210799A1/ko unknown
- 2021-03-23 JP JP2022562440A patent/JP2023522628A/ja active Pending
- 2021-03-23 CN CN202180028319.3A patent/CN115427039A/zh active Pending
- 2021-03-23 BR BR112022020649A patent/BR112022020649A2/pt unknown
- 2021-03-23 AU AU2021255160A patent/AU2021255160B2/en active Active
- 2021-03-23 CA CA3172596A patent/CA3172596A1/en active Pending
- 2021-03-23 MX MX2022012726A patent/MX2022012726A/es unknown
- 2021-03-23 US US17/918,497 patent/US20230148365A1/en active Pending
- 2021-11-24 KR KR1020210162964A patent/KR102567012B1/ko active IP Right Grant
-
2022
- 2022-03-16 KR KR1020220032891A patent/KR20220039687A/ko active Search and Examination
- 2022-09-27 CL CL2022002642A patent/CL2022002642A1/es unknown
- 2022-10-05 CO CONC2022/0014273A patent/CO2022014273A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021255160B2 (en) | 2024-02-01 |
| AU2021255160A1 (en) | 2022-10-06 |
| BR112022020649A2 (pt) | 2022-11-29 |
| US20230148365A1 (en) | 2023-05-11 |
| CO2022014273A2 (es) | 2022-10-21 |
| CA3172596A1 (en) | 2021-10-21 |
| JP2023522628A (ja) | 2023-05-31 |
| KR20220039687A (ko) | 2022-03-29 |
| EP4137134A1 (en) | 2023-02-22 |
| MX2022012726A (es) | 2022-11-07 |
| KR102567012B1 (ko) | 2023-08-14 |
| KR20210146871A (ko) | 2021-12-06 |
| CN115427039A (zh) | 2022-12-02 |
| WO2021210799A1 (ko) | 2021-10-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2022008344A2 (es) | Derivados de pirazolilo útiles como agentes anticancerígenos | |
| CO2019015090A2 (es) | Métodos de tratamiento para la fibrosis cística | |
| ECSP22071009A (es) | Derivados de biarilo como inhibidores de la interacción proteína-proteína de yap/taz-tead | |
| CO2018005842A2 (es) | Composición farmacéutica que comprende un potente inhibidor de urat 1 | |
| CL2022003360A1 (es) | Benzofurano, benzopirrol, benzotiofeno sustituidos y otros inhibidores del complemento estructuralmente relacionados (divisional de la solicitud 202002578) | |
| UY37941A (es) | Derivados de bencimidazol y sus usos | |
| CL2022000875A1 (es) | Inhibidores del factor d del complemento para administración oral | |
| CL2022002641A1 (es) | Agente para el tratamiento de lesión renal aguda inducida por medio de contraste | |
| CL2023000200A1 (es) | Nuevo derivado de pirazol | |
| CO2022008616A2 (es) | Composición farmacéutica oral que comprende compuesto de carbamato y método de preparación para la misma | |
| CO2019004004A2 (es) | Composición farmacéutica y método para el tratamiento de la enfermedad del hígado graso no alcohólico | |
| CL2023000418A1 (es) | Derivados de espiropiperidinilo sustituidos con heteroarilo y usos farmacéuticos de los mismos | |
| WO2020128816A3 (en) | Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent | |
| ECSP19084722A (es) | Compuestos bicíclicos 5,6-fusionados y composiciones para el tratamiento de enfermedades parasitarias | |
| CU20200102A7 (es) | Compuestos derivados de isoindolin-1,2,4-triazol-3-carbonitrilo útiles para el tratamiento de enfermedades cinetoplastídicas | |
| AR114418A1 (es) | Compuesto cíclico de metilactama y su utilización farmacéutica | |
| CL2022002642A1 (es) | Medicamentos para fibrosis pulmonar que contienen derivado de pirazol | |
| CO2023006912A2 (es) | Nuevos derivados de indazol acetileno | |
| EA202190316A1 (ru) | Конденсированное производное лактама | |
| ECSP22054240A (es) | Compuesto y composici?n como inhibidor de quinasa del receptor pdgf | |
| AR126552A1 (es) | Composición farmacéutica para prevenir o tratar la esclerosis sistémica | |
| AR117988A1 (es) | Medicamento para profilaxis o tratamiento para la fibrosis pulmonar | |
| UY39649A (es) | Compuesto para el tratamiento de trastornos cognitivos | |
| AR126393A1 (es) | Terapia combinada para el tratamiento de enfermedades hepáticas | |
| AR126892A1 (es) | Compuestos de aminopiridina sustituidos como inhibidores de egfr |